Brooks M Boyd

USPTO Granted Patents = 17 (Patent Applications = 26)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 2.3

ph-index = 8

Forward Citations = 101(Granted Patents)

Company Filing History:

10 out of 21

Zogenix International Limited

Years Active: 2004-2023

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11786487 - Formulation for inhibiting formation of 5-HTagonists and methods of using same (2023-10-17),

2. 11759440 - Formulation for inhibiting formation of 5-HTagonists and methods of using same (2023-09-19),

3. 11673852 - Metabolism resistant fenfluramine analogs and methods of using the same (2023-06-13),

4. 11458111 - Ketogenic diet compatible fenfluramine formulation (2022-10-04),

5. 11406606 - Formulation for inhibiting formation of 5-HT2B agonists and methods of using same (2022-08-09),

6. 11325882 - Metabolism resistant fenfluramine analogs and methods of using the same (2022-05-10),

7. 11040018 - Formulation for inhibiting formation of 5-HT2B agonists and methods of using same (2021-06-22),

8. 10689324 - Metabolism resistant fenfluramine analogs and methods of using the same (2020-06-23),

9. 10682317 - Ketogenic diet compatible fenfluramine formulation (2020-06-16),

10. 10603290 - Formulation for inhibiting formation of 5-HTagonists and methods of using same (2020-03-31),

11. 9662449 - Needle-free injectors and design parameters thereof that optimize injection performance (2017-05-30),

12. 9265888 - Needle-free injectors and design parameters thereof that optimize injection performance (2016-02-23),

13. 9186461 - Viscous formulations and their use in needle-free injection (2015-11-17),

14. 8876758 - Viscous formulations and their use in needle-free injection (2014-11-04),

15. 8734384 - Needle-free injectors and design parameters thereof that optimize injection performance (2014-05-27),

Title: **Brooks M Boyd: Innovator in Pharmacological Advancements**

Introduction

Brooks M Boyd, an esteemed inventor based in Berkeley, California, has made significant contributions to the field of pharmacology. With a total of 17 patents to his name, Boyd's innovations primarily focus on drug formulations that enhance safety and efficacy in medical treatment.

Latest Patents

Among his latest patents, Boyd's formulation for inhibiting the formation of 5-HT agonists deserves special attention. This innovative approach involves the administration of a first drug, such as fenfluramine, in conjunction with a second drug, which acts as a CYP inhibitor like cannabidiol. This combination modulates the formation of harmful metabolites, thus making the initial drug safer for patients and reducing the known adverse side effects associated with 5-HT agonist metabolites.

Career Highlights

Throughout his career, Brooks M Boyd has been affiliated with notable companies in the pharmaceutical industry, including Zogenix International Limited and Zogenix, Inc. His extensive experience in these organizations has allowed him to influence the development of safe and effective drug therapies.

Collaborations

Boyd has worked alongside prominent professionals such as Stephen J Farr and Jeffrey A Schuster. These collaborations have not only enriched his research but have also fostered a collaborative environment that aims to push the boundaries of medical innovation.

Conclusion

Brooks M Boyd exemplifies the dedication and ingenuity of modern inventors in the field of drug development. His relentless pursuit of safer medications through innovative formulations highlights the importance of research and collaboration in creating impactful medical advancements. As he continues to develop patents that address critical health concerns, Boyd remains a key figure in the evolution of pharmacological treatments.

This text is generated by artificial intelligence and may not be accurate.